Activities

Task Forces of the ENT Section



                                               Passionate about Allergy and Rhinology... 



(40026) TF - Intranasal Trigeminal system and its link to allergic and non allergic rhinitis

The intranasal trigeminal nerve is a full sensory organ innervating the nasal mucosa, functionally organized, responsible for both the nasal patency perception and the chemosensory perception and also responsible to a certain degree of nasal inflammation . Protection of  the upper and lower airways for potential life-threatening substances acting as a sentinel to shorten or stop inspiration reflexively is the primary function of the intranasal trigeminal system in the upper airway.  The intranasal trigeminal system also helps to the global chemosensory perception with the olfactory system. Indeed, the global perception of a chemosensory stimulus requires both olfactory and trigeminal information. Most of the odorants are capable of stimulating both systems at least at high concentrations. The olfactory system is more dedicated in identification task for hedonicity and alimentary behavioral, recognition and memory, behavioral and social comportments than the trigeminal system that is probably more oriented to protective function and reflexe

(40027) TF - Topical treatment of upper airway inflammations; Efficacy, Safety, Devices

and Patient Preferences



(40028) TF - Diagnostic role of smell tests in Upper Airway Inflammation



(40029) TF - The Harm Of Longterm Use Of Systemic Steroids In Rhinitis and Rhinosinusitis

Allergic respiratory  diseases have increased over the past decades  and currently amost 30 %  of the population suffer from allergic rhinitis. Some of the most comprehensive classification and treatment recommendations for rhinitis can be found in the Allergic Rhinitis and it’s Impact on Asthma (ARIA) guidelines.  Rhinosinusitis  with  and  without  nasal  polyps  affects  around  14  %  of  the  population  and the  management  and  recommendations  for  these  diseases  are  described  in  the  European  Position Paper on Rhinosinusitis and Nasal Polyps (EPOS). Systemic corticosteroids are only recommended in the most severe cases of rhinitis and rhinosinutis; and solely in a short-term oral treatment scheme. However,  depot-injections  of  corticosteroids  or  long-term  oral  corticosteroids  are  regularly  used  to treat   allergic   rhinitis   or   rhinosinusitis.   However,   it   has   been   demonstrated   that   systemic corticosteroids  only  have  a  very  short-term  effect  in  nasal  polyposis  patients,   in  addition  to a rebound tissue eosinophilia after withdrawal.  Additionally, severe  adverse events such as avascular necrosis,  adrenal  suppression,  osteoporosis  and  diabetes due  to systemic  steroid  use,  have  been reported  previously.  The  aim  of  this  task  force  is  to  discuss  the  disadvantages  of  long-term  and repeated  short-term  courses  of  systemic  steroids  as  a  treatment  strategy  for  upper  airway  disease and  to  suggest  alternative  and  better  therapeutic  options  for  these  disease  entities,  such  as  e.g. immunotherapy.


(400211) Position Paper On The Standardisation Of Nasal Allergen Challenge.


 

 

 



 
 
 
 
 
 
 

                                                                                                                                                                             .

Last updated 23 November 2017
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel